"Parkinson's disease is associated with depletion of tyrosine hydroxylase, dopamine, serotonin, and norepinephrine. "
From "Amino acid management of Parkinson's disease: a case study."; full text is available-
1. Int J Gen Med. 2011 Feb 28;4:165-74.
Amino acid management of Parkinson's disease: a case study.
Hinz M, Stein A, Uncini T.
Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA;
An extensive list of side effects and problems are associated with the
administration of l-dopa (l-3, 4-dihydroxyphenylalanine) during treatment of
Parkinson's disease. These problems can preclude achieving an optimal response
with l-dopa treatment.PURPOSE: To present a case study outlining a novel approach
for the treatment of Parkinson's disease that allows for management of problems
associated with l-dopa administration and discusses the scientific basis for this
treatment.
PATIENTS AND METHODS: The case study was selected from a database containing 254
Parkinson's patients treated in developing and refining this novel approach to
its current state. The spectrum of patients comprising this database range from
newly diagnosed, with no previous treatment, to those who were diagnosed more
than 20 years before and had virtually exhausted all medical treatment options.
Parkinson's disease is associated with depletion of tyrosine hydroxylase,
dopamine, serotonin, and norepinephrine. Exacerbating this is the fact that
administration of l-dopa may deplete l-tyrosine, l-tryptophan,
5-hydroxytryptophan (5-HTP), serotonin, and sulfur amino acids. The properly
balanced administration of l-dopa in conjunction with 5-HTP, l-tyrosine,
l-cysteine, and cofactors under the guidance of organic cation transporter
functional status determination (herein referred to as "OCT assay
interpretation") of urinary serotonin and dopamine, is at the heart of this novel
treatment protocol.
RESULTS: When 5-HTP and l-dopa are administered in proper balance along with
l-tyrosine, l-cysteine, and cofactors under the guidance of OCT assay
interpretation, the long list of problems that can interfere with optimum
administration of l-dopa becomes controllable and manageable or does not occur at
all. Patient treatment then becomes more effective by allowing the implementation
of the optimal dosing levels of l-dopa needed for the relief of symptoms without
the dosing value barriers imposed by side effects and adverse reactions seen in
the past.
PMCID: PMC3068871
PMID: 21475622 [PubMed]
__________________
Born in 1953, 1st symptoms and misdiagnosed as essential tremor in 1992. Dx with PD in 2000.
Currently (2011) taking 200/50 Sinemet CR 8 times a day + 10/100 Sinemet 3 times a day. Functional 90% of waking day but fragile. Failure at exercise but still trying. Constantly experimenting. Beta blocker and ACE inhibitor at present. Currently (01/2013) taking ldopa/carbadopa 200/50 CR six times a day + 10/100 form 3 times daily. Functional 90% of day. Update 04/2013: L/C 200/50 8x; Beta Blocker; ACE Inhib; Ginger; Turmeric; Creatine; Magnesium; Potassium. Doing well.
|
Linear Mode
